NAS10028,437+0.91%S&P7,689+1.58%GOLD$4,142+1.70%BTC$80,182−0.28%VIX16.80+1.14%latest tape · as of 12:01 UTC
The Screen · Technology · Computer Hardware
Sandisk
SNDK · a US exchange · USD · Market cap $181.5B · 11,000 employees
Sandisk Corporation develops, manufactures, and sells data storage devices and solutions using NAND flash technology in the United States, Europe, the Middle East, Africa, Asia, and internationally.
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 2.39, read 2026-11-05
Ethical passes the values gate
Price1,037.40 USD
Fair valueUnder review
Ethical score88.4/100
Our investment reviews on this name
2026-10-11Read Markdown1,777.80-41.6% to today ✓Accumulation gives way to Markdown
2026-09-13Read Accumulation1,737.99-40.3% to today Distribution gives way to Accumulation after a 29% rise in 4 weeks
2026-08-13Read Distribution1,350.50-23.2% to today ✓Markup gives way to Distribution after a 13% slide in 6 weeks
2026-07-02Read Markup1,559.32-33.5% to today First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Sandisk holds its Markdown at $1,037.40. The statistical read favours the sellers, held for 42 days.
As held on the ledger · 2026-11-04
Phase
Markdown · caution
Quantitative state
The statistical read favours the sellers, held for 42 days
Price at the screen
$1,037.40
Valuation
17.02 trailing · 4.71 forward price to earnings
Values screen
PASS· score 88.4
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
15.73%
Below 33%
Interest-bearing debt is just 15.7% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
19.63%
Below 49%
Money owed to the company is 19.6% of assets, under the 49% limit.
Pass
Revenue purity
0.30%
Below 5%
Only 0.3% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Sandisk clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 16%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when SNDK's ethical verdict changes
Today SNDK passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Fair value under review. Our model's value is 2.59x the price, above our 2.00x limit. We show no fair value, margin of safety or value read built on it until the review clears.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
SNDK trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-05Markdown$1,037.40-26.2%Entry 17
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 26.2% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 0% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 3851%. Our forward projection puts the odds of a 10% gain over the next month near 73%. The street (22 analysts) rates it buy, with a mean price target of $1493.
2026-10-29Markdown$1,404.77+11.9%Entry 16
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 11.9% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 0% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 3851%. Our forward projection puts the odds of a 10% gain over the next month near 73%. The street (22 analysts) rates it buy, with a mean price target of $1493. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Markdown$1,255.58+0.0%Entry 15
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 0% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 3851%. Our forward projection puts the odds of a 10% gain over the next month near 73%. The street (22 analysts) rates it buy, with a mean price target of $1493. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Markdown$1,255.58-10.0%Entry 14
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 10.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 0% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 3851%. Our forward projection puts the odds of a 10% gain over the next month near 73%. The street (22 analysts) rates it buy, with a mean price target of $1493. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26Markdown$1,394.83+0.0%Entry 13
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 0% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 3851%. Our forward projection puts the odds of a 10% gain over the next month near 73%. The street (22 analysts) rates it buy, with a mean price target of $1493. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Markdown$1,394.83+0.0%Entry 12
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 7% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 3851%. Our forward projection puts the odds of a 10% gain over the next month near 73%. The street (22 analysts) rates it buy, with a mean price target of $1493. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24Markdown$1,394.83+0.0%Entry 11
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 7% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 3851%. Our forward projection puts the odds of a 10% gain over the next month near 73%. The street (22 analysts) rates it buy, with a mean price target of $1493. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23Markdown$1,394.83+0.0%Entry 10
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 7% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 3851%. Our forward projection puts the odds of a 10% gain over the next month near 73%. The street (22 analysts) rates it buy, with a mean price target of $1493. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-22Markdown$1,394.83+0.0%Entry 9
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 7% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 3851%. Our forward projection puts the odds of a 10% gain over the next month near 73%. The street (22 analysts) rates it buy, with a mean price target of $1493. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-18Markdown$1,394.83-21.5%Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 21.5% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 242% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 3851%. Our forward projection puts the odds of a 10% gain over the next month near 73%. The street (22 analysts) rates it buy, with a mean price target of $1493.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
